Dr. Reddy’s Laboratories Ltd. expects its generic anti-obesity drug to help boost growth in the six months through March after resolving an impurity issue with the key ingredient and resuming supply in early November, according to Bloomberg.

The company had faced a setback tied to the ingredient problem, but it now sees the product as a contributor to growth over the period.